- Date October 2020
- Therapeutic Area Idiopathic Pulmonary Fibrosis
- Challenges Covid-19 pandemic | Rare disease | High patient burden (1 year-long commitment)



Phase II Clinical Study for Patients with IPF
Responsum was brought in to boost enrollment in the US market quickly. This was the first time Responsum supported a clinical trial campaign.
Strategy:
Leveraging our 3.6K+ member pulmonary fibrosis community, we launched a targeted campaign centered on clinical trial education, streamlined phone screening, and a personalized email drip campaign designed to align with participants’ preferences and demographics.
52 patients were referred successfully, 13 screened, and 8 randomized. All from our IPF community.


“We got 300% grown result from being at a coworking space compared to working from home/coffee shops. We’re far more settled and happy in this company!”